ESTRO 2025 - Abstract Book

S1439

Clinical - Lung

ESTRO 2025

[2]

Faivre-Finn C et al. https://doi.org/10.1016/S1470-2045(17)30318-2.

[3] Turrisi AT et al. https://doi.org/10.1056/NEJM199901283400403/ASSET/6B099F54-A4BD-4300-8865 C51EDE5087BA/ASSETS/IMAGES/LARGE/NEJM199901283400403_F1.JPG. [4] Schreiber D et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer. https://doi.org/10.1002/CNCR.24853. [5] Dingemans AMC et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. https://doi.org/10.1016/J.ANNONC.2021.03.207/ATTACHMENT/D07623EC-1012-48DA-A0B2 120374C92241/MMC1.PDF.

4410

Digital Poster Is the SOCCAR Regimen Now a Standard Treatment? Mariela Rojas 1 , Marta López Valcárcel 2 , Irma Zapata Paz 2 , Joaquín Velasco Jiménez 1 1 Radiation Oncology, Hospital Universitario Puerta de Hierro, Madrid, Spain. 2 Radiation Oncology, Hospital universitario puerta de hierro, Madrid, Spain Purpose/Objective: This study aimed to evaluate the clinical outcomes and toxicity of the SOCCAR regimen in patients with locally advanced, unresectable, or inoperable non-small cell lung cancer (NSCLC) at our center. Specifically, the analysis focused on the combination of radiotherapy with concurrent chemotherapy and/or neoadjuvant therapy. Material/Methods: The study included patients with locally advanced NSCLC treated between April 2020 and April 2024. Radiotherapy was delivered using intensity-modulated radiation therapy (IMRT) or image-guided radiation therapy (IGRT) at a dose of 55 Gy across 20 fractions. Concurrent weekly carboplatin-taxol or oral vinorelbine-based chemotherapy was administered, with some patients receiving additional neoadjuvant chemotherapy using platinum-vinorelbine and/or nivolumab. Toxicity was evaluated using CTCAE v5.0 criteria, while survival analyses were performed using Kaplan-Meier curves and T-tests. Results: The cohort consisted of 26 patients (median age: 73.5 years; IQR: 67.5–79.5), including 20 men and 6 women. Histological subtypes included 10 adenocarcinomas and 16 squamous cell carcinomas, with staging as follows: 12 IIIA, 11 IIIB, and 3 IIIC. Fourteen patients underwent neoadjuvant chemotherapy. Concurrent chemotherapy regimens included weekly carboplatin-taxol in 16 patients and vinorelbine in 10 patients. With a median follow-up of 30 months (95% CI: 19.9–39.9), the study reported local recurrence-free survival rates of 62.2% at 1 year and 46.6% at 2 years. Distant recurrence-free survival was 58.3% at both 1 and 2 years, while overall survival (OS) was 53.2% at 1 and 2 years. Notably, both weekly carboplatin-taxol (p = 0.012) and neoadjuvant chemotherapy (p = 0.011) were associated with significant improvements in OS. Treatment-related toxicities included grade 1 and grade 2 esophagitis in 23.1% and 65.4% of patients, respectively, and grade 2 pneumonitis in 7.7%. Conclusion: The SOCCAR regimen, when combined with concurrent chemotherapy and/or neoadjuvant therapy, demonstrated promising clinical outcomes in terms of survival and local disease control for patients with locally advanced NSCLC. Importantly, the treatment was well tolerated, with manageable toxicity profiles. These findings support the ongoing use of this approach in clinical practice and highlight the need for further investigation to validate its efficacy and safety in larger patient populations.

Keywords: SOCCAR, STANDARD